Catalyst Pharmaceuticals Inc (CPRX)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	163,889	142,797	68,149	65,117	71,410	62,037	115,549	99,406	83,079	66,917	54,498	45,060	39,482	41,610	74,621	72,220	74,983	71,476	41,766	42,946
Total assets	US$ in thousands	851,411	772,010	706,360	646,676	471,907	413,211	443,896	407,227	375,630	333,114	267,309	246,972	237,788	223,248	209,130	197,216	192,354	174,860	131,412	117,880
ROA		19.25%	18.50%	9.65%	10.07%	15.13%	15.01%	26.03%	24.41%	22.12%	20.09%	20.39%	18.24%	16.60%	18.64%	35.68%	36.62%	38.98%	40.88%	31.78%	36.43%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $163,889K ÷ $851,411K
= 19.25%

The return on assets (ROA) of Catalyst Pharmaceuticals Inc has shown some fluctuations over the periods in question.

Between March 31, 2020, and December 31, 2020, the ROA ranged from around 31.78% to 40.88%, indicating relatively strong performance in utilizing its assets to generate profit. However, from September 30, 2021, to June 30, 2022, the ROA decreased to a range of 16.60% to 20.39%, signaling a decline in asset efficiency during this period.

From March 31, 2023, to December 31, 2024, there was some volatility in the ROA, fluctuating between 9.65% and 26.03%. The ROA showed an upward trend from the lowest point up to 26.03% by June 30, 2023, after which there was a slight decrease to 15.01% by September 30, 2023. Subsequently, there was another minor increase up to 19.25% by December 31, 2024.

Overall, while the ROA of Catalyst Pharmaceuticals Inc exhibited variation over the periods, it is important to further investigate the factors driving these fluctuations to understand the company's effectiveness in generating profit from its assets and to assess its operational efficiency and financial performance in the long term.